Mumbai, September 5 (Kiran News) — Shares of Biocon were trading higher on Friday after the company announced that the US Food and Drug Administration (USFDA) had completed a routine cGMP inspection at the drug substance facility of its subsidiary Biocon Biologics (BBL) in Bengaluru.
At 11:00 am, the stock was quoted at ₹361.60, up 1.32% from its previous close of ₹356.90 on the BSE. The scrip opened at ₹353.15 and touched an intraday high of ₹364.80 and a low of ₹353.15. A total of 40,631 shares were traded on the counter.
The BSE ‘A’ group stock, with a face value of ₹5, has a 52-week high of ₹405.90 (July 18, 2025) and a 52-week low of ₹290.80 (March 3, 2025). The company’s market capitalisation currently stands at ₹48,505.04 crore. Promoters hold 54.45%, while institutional and non-institutional investors own 28.86% and 16.68% respectively.
The inspection, conducted between August 26 and September 3, 2025, covered drug substance manufacturing units, analytical QC labs, microbiology labs, and warehouses. At its conclusion, the USFDA issued a Form 483 with five observations, which the company clarified were procedural in nature and not related to data integrity, systemic non-compliance, or quality oversight.
Biocon Biologics will submit a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated time frame and expressed confidence in addressing all observations promptly. The company also stated that there would be no impact on the supply of its commercial products.
Biocon is India’s largest and Asia’s leading biotechnology company, focused on biopharmaceuticals and research services. It is an integrated, innovation-driven biopharma enterprise offering affordable healthcare solutions for chronic diseases worldwide.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
